|
Pharming Group N.V. (PHAR) DCF Valuation |
Fully Editable: Tailor To Your Needs In Excel Or Sheets
Professional Design: Trusted, Industry-Standard Templates
Investor-Approved Valuation Models
MAC/PC Compatible, Fully Unlocked
No Expertise Is Needed; Easy To Follow
Pharming Group N.V. (PHAR) Bundle
Looking to evaluate the intrinsic value of Pharming Group N.V.? Our (PHAR) DCF Calculator integrates real-world data with extensive customization features, enabling you to refine your projections and enhance your investment choices.
Discounted Cash Flow (DCF) - (USD MM)
| Year | AY1 2020 |
AY2 2021 |
AY3 2022 |
AY4 2023 |
AY5 2024 |
FY1 2025 |
FY2 2026 |
FY3 2027 |
FY4 2028 |
FY5 2029 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 259.4 | 215.6 | 233.5 | 278.6 | 325.8 | 348.3 | 372.4 | 398.2 | 425.8 | 455.2 |
| Revenue Growth, % | 0 | -16.88 | 8.31 | 19.3 | 16.95 | 6.92 | 6.92 | 6.92 | 6.92 | 6.92 |
| EBITDA | 104.6 | 55.4 | 38.1 | 11.2 | 8.2 | 61.9 | 66.2 | 70.8 | 75.7 | 80.9 |
| EBITDA, % | 40.33 | 25.69 | 16.31 | 4.03 | 2.51 | 17.77 | 17.77 | 17.77 | 17.77 | 17.77 |
| Depreciation | 9.4 | 22.3 | 15.0 | 18.1 | 17.6 | 22.5 | 24.0 | 25.7 | 27.5 | 29.4 |
| Depreciation, % | 3.64 | 10.33 | 6.41 | 6.49 | 5.41 | 6.46 | 6.46 | 6.46 | 6.46 | 6.46 |
| EBIT | 95.2 | 33.1 | 23.1 | -6.9 | -9.5 | 39.4 | 42.1 | 45.1 | 48.2 | 51.5 |
| EBIT, % | 36.69 | 15.36 | 9.89 | -2.47 | -2.9 | 11.32 | 11.32 | 11.32 | 11.32 | 11.32 |
| Total Cash | 233.4 | 217.7 | 235.5 | 242.4 | 184.0 | 302.0 | 322.9 | 345.2 | 369.1 | 394.7 |
| Total Cash, percent | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Account Receivables | 21.9 | 18.0 | 22.2 | 48.4 | 60.4 | 43.3 | 46.3 | 49.6 | 53.0 | 56.6 |
| Account Receivables, % | 8.43 | 8.37 | 9.52 | 17.37 | 18.53 | 12.44 | 12.44 | 12.44 | 12.44 | 12.44 |
| Inventories | 24.1 | 31.0 | 48.1 | 64.5 | 61.1 | 60.0 | 64.1 | 68.6 | 73.3 | 78.4 |
| Inventories, % | 9.28 | 14.37 | 20.58 | 23.14 | 18.75 | 17.22 | 17.22 | 17.22 | 17.22 | 17.22 |
| Accounts Payable | 15.3 | 5.8 | 6.9 | 16.5 | 73.0 | 27.8 | 29.7 | 31.8 | 34.0 | 36.3 |
| Accounts Payable, % | 5.9 | 2.71 | 2.95 | 5.92 | 22.41 | 7.98 | 7.98 | 7.98 | 7.98 | 7.98 |
| Capital Expenditure | -18.7 | -18.1 | -2.2 | -1.7 | -.9 | -12.2 | -13.0 | -13.9 | -14.9 | -15.9 |
| Capital Expenditure, % | -7.21 | -8.41 | -0.96147 | -0.59678 | -0.27746 | -3.49 | -3.49 | -3.49 | -3.49 | -3.49 |
| Tax Rate, % | -29.53 | -29.53 | -29.53 | -29.53 | -29.53 | -29.53 | -29.53 | -29.53 | -29.53 | -29.53 |
| EBITAT | 75.7 | 24.0 | 21.1 | -6.0 | -12.2 | 34.0 | 36.3 | 38.9 | 41.6 | 44.4 |
| Depreciation | ||||||||||
| Changes in Account Receivables | ||||||||||
| Changes in Inventories | ||||||||||
| Changes in Accounts Payable | ||||||||||
| Capital Expenditure | ||||||||||
| UFCF | 35.8 | 15.6 | 13.6 | -22.6 | 52.4 | 17.2 | 42.2 | 45.1 | 48.2 | 51.5 |
| WACC, % | 6.98 | 6.97 | 7 | 6.99 | 7.01 | 6.99 | 6.99 | 6.99 | 6.99 | 6.99 |
| PV UFCF | ||||||||||
| SUM PV UFCF | 163.3 | |||||||||
| Long Term Growth Rate, % | 2.00 | |||||||||
| Free cash flow (T + 1) | 53 | |||||||||
| Terminal Value | 1,053 | |||||||||
| Present Terminal Value | 751 | |||||||||
| Enterprise Value | 915 | |||||||||
| Net Debt | 63 | |||||||||
| Equity Value | 852 | |||||||||
| Diluted Shares Outstanding, MM | 689 | |||||||||
| Equity Value Per Share | 1.24 |
What You Will Get
- Real Pharming Data: Preloaded financials – from revenue to EBIT – based on actual and projected figures.
- Full Customization: Adjust all critical parameters (yellow cells) like WACC, growth %, and tax rates.
- Instant Valuation Updates: Automatic recalculations to analyze the impact of changes on Pharming Group N.V. (PHAR)’s fair value.
- Versatile Excel Template: Tailored for quick edits, scenario testing, and detailed projections.
- Time-Saving and Accurate: Skip building models from scratch while maintaining precision and flexibility.
Key Features
- Comprehensive DCF Calculator: Features detailed unlevered and levered DCF valuation models tailored for Pharming Group N.V. (PHAR).
- WACC Calculator: Includes a pre-built Weighted Average Cost of Capital sheet with adjustable inputs specific to the pharmaceutical industry.
- Customizable Forecast Assumptions: Adjust growth rates, capital expenditures, and discount rates to fit Pharming Group N.V. (PHAR) projections.
- Integrated Financial Ratios: Evaluate profitability, leverage, and efficiency ratios relevant to Pharming Group N.V. (PHAR).
- Interactive Dashboard and Charts: Visual representations summarize essential valuation metrics for straightforward analysis.
How It Works
- Step 1: Download the prebuilt Excel template with Pharming Group N.V. (PHAR) data included.
- Step 2: Explore the pre-filled sheets and understand the key metrics related to Pharming Group N.V. (PHAR).
- Step 3: Update forecasts and assumptions in the editable yellow cells (WACC, growth, margins) specific to Pharming Group N.V. (PHAR).
- Step 4: Instantly view recalculated results, including Pharming Group N.V. (PHAR)'s intrinsic value.
- Step 5: Make informed investment decisions or generate reports using the outputs for Pharming Group N.V. (PHAR).
Why Choose This Calculator for Pharming Group N.V. (PHAR)?
- Accurate Data: Up-to-date Pharming financials provide dependable valuation outcomes.
- Customizable: Modify essential parameters such as growth rates, WACC, and tax rates to align with your forecasts.
- Time-Saving: Built-in calculations save you from starting from the ground up.
- Professional-Grade Tool: Tailored for investors, analysts, and consultants in the biotech sector.
- User-Friendly: Clear layout and step-by-step guidance make it accessible for all users.
Who Should Use This Product?
- Professional Investors: Develop comprehensive and accurate valuation models for portfolio evaluation in Pharming Group N.V. (PHAR).
- Corporate Finance Teams: Assess valuation scenarios to inform strategic decisions within their organizations.
- Consultants and Advisors: Deliver precise valuation insights for clients interested in Pharming Group N.V. (PHAR).
- Students and Educators: Leverage real-world data to enhance learning and practice in financial modeling.
- Healthcare Analysts: Gain insights into how biotech companies like Pharming Group N.V. (PHAR) are valued in the market.
What the Template Contains
- Pre-Filled Data: Includes Pharming Group N.V.'s historical financials and forecasts.
- Discounted Cash Flow Model: Editable DCF valuation model with automatic calculations.
- Weighted Average Cost of Capital (WACC): A dedicated sheet for calculating WACC based on custom inputs.
- Key Financial Ratios: Analyze Pharming Group N.V.'s profitability, efficiency, and leverage.
- Customizable Inputs: Edit revenue growth, margins, and tax rates with ease.
- Clear Dashboard: Charts and tables summarizing key valuation results.
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.